Dr Timothy Schulz-Utermoehl

Dr. Timothy Schulz-Utermoehl is an experienced director and scientific advisor with a strong background in biochemistry and toxicology. Dr. Schulz-Utermoehl holds a Ph.D. in Biochemistry from Imperial College London and an M.Sc. in Toxicology from the Royal Postgraduate Medical School, University of London. Notable positions include Director at DMPK Consulting Limited, Head of Preclinical Development and Head of DMPK at Pheno Therapeutics Ltd, and Co-founder at several companies including Pandeia Therapeutics, Blacksand Therapeutics, and Pencil Biosciences Limited.